Molecular structure of L-Thyroxine, free acid, CAS Number: 51-48-9
L-Thyroxine, free acid (CAS 51-48-9)
See product citations (2)
Alternate Names:
(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3, 5-diiodophenyl]propanoic acid
Application:
L-Thyroxine, free acid is L-Thyroxine was used to study the light-induced hormone conversion of T4 to T3 in regulation of photoperiodic response of gonads in Japanese quail. The product was used as a test compound for studying the impact of numerous hormones on the surface morphology of rat testicular cells in culture.
CAS Number:
51-48-9
Purity:
≥98%
Molecular Weight:
776.87
Molecular Formula:
C15H11I4NO4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
L-Thyroxine, free acid is a thyroid hormone integral to regulating metabolic processes and cellular growth. Its primary action is mediated through binding with thyroid hormone receptors located within the nucleus of target cells. This interaction facilitates a cascade of genetic transcriptional changes that are in the modulation of metabolic rate, utilization of energy substrates such as glucose and fatty acids, and orchestration of protein synthesis. The hormone′s role extends to influencing the differentiation processes of cells, which is for proper cellular function and development. Through these mechanisms, L-Thyroxine, free acid significantly impacts cellular metabolism and energy production, thereby playing a key role in maintaining cellular homeostasis and supporting the physiological demands of growth and development.
L-Thyroxine, free acid (CAS 51-48-9) References
- L-thyroxine prevents the bone-conserving effect of HRT in postmenopausal women with subclinical hypothyroidism. | Pines, A., et al. 1999. Gynecol Endocrinol. 13: 196-201. PMID: 10451812
- L-thyroxine treatment in primary hypothyroidism does not increase the content of free triiodothyronine in cerebrospinal fluid: a pilot study. | Sjöberg, S., et al. 2011. Scand J Clin Lab Invest. 71: 63-7. PMID: 21214501
- 2013 ETA Guideline: Management of Subclinical Hypothyroidism. | Pearce, SH., et al. 2013. Eur Thyroid J. 2: 215-28. PMID: 24783053
- Potential of l-thyroxine to differentiate osteoblast-like cells via Angiopoietin1. | Park, SH., et al. 2016. Biochem Biophys Res Commun. 478: 1409-15. PMID: 27569283
- l-Thyroxine in an Oral Liquid or Softgel Formulation Ensures More Normal Serum Levels of Free T4 in Patients with Central Hypothyroidism. | Benvenga, S., et al. 2017. Front Endocrinol (Lausanne). 8: 321. PMID: 29209276
- L-Thyroxine intake as a potential risk factor for the development of fatigue in breast cancer patients undergoing chemotherapy. | Schmidt, ME., et al. 2018. Support Care Cancer. 26: 2561-2569. PMID: 29445858
- AdipoRon prevents l-thyroxine or isoproterenol-induced cardiac hypertrophy through regulating the AMPK-related pathway. | Hu, X., et al. 2019. Acta Biochim Biophys Sin (Shanghai). 51: 20-30. PMID: 30566571
- Relation of Gut Microbes and L-Thyroxine Through Altered Thyroxine Metabolism in Subclinical Hypothyroidism Subjects. | Yao, Z., et al. 2020. Front Cell Infect Microbiol. 10: 495. PMID: 33072620
- Cardioprotection of an IK1 channel agonist on L-thyroxine induced rat ventricular remodeling. | Liu, QH., et al. 2021. Am J Transl Res. 13: 8683-8696. PMID: 34539987
- Comparison Among Two Liquid Formulations of L-thyroxine in the Treatment of Congenital Hypothyroidism in the First Month of Life: A Pilot Study. | Tuli, G., et al. 2022. Front Endocrinol (Lausanne). 13: 860775. PMID: 35480479
- An Overview on Different L-Thyroxine (l-T4) Formulations and Factors Potentially Influencing the Treatment of Congenital Hypothyroidism During the First 3 Years of Life. | Stagi, S., et al. 2022. Front Endocrinol (Lausanne). 13: 859487. PMID: 35757415
- The effect of L-thyroxine treatment on ventricular dysfunction and pulmonary arterial stiffness in patients with subclinical hypothyroidism. | Çamci, S., et al. 2022. Eur Rev Med Pharmacol Sci. 26: 7036-7045. PMID: 36263551
- L-thyroxine overdose: a case of marked, severe, prolonged, excess ingestion and review of the literature. | Shapiro, B., et al. 1993. Thyroidology. 5: 61-6. PMID: 7522533
Inhibitor of:
ALB, APO, GLIS3, Gm8267, and PMP22.Activator of:
α-lactalbumin, γE-crystallin, κ-casein, AbdA, ACE, ADAM3, AK4, Aldolase A, Amylase 1, Amylase 2A, Amylase 2B, Biotin, c-Erb-A α-1, c-Erb-A α-2, c-Erb-A β-2, C20orf79, CD98, CHT1, Creatine Kinase, CRTAC1, CSGlcA-T, DAZL, DEHAL1, ELOVL3, fetuin-B, GABP-β2, GHR, Glucose, Gm694, hCG_15200, HCR, HoxA11, HR, ITF-2, Keratin 37, KIR3DL3, KRTAP10-2, KRTAP10-9, KRTAP19-2, KRTAP19-5, KRTAP19-6, KRTAP21-2, KRTAP24-1, KRTAP4-2, KV2.1, L-Alkaline phosphatase, L-Glycerol-3-Phosphate Oxidase, L-type Ca++ CP γ1, LDLR, Lipophilin A, Lipophilin B, LOC257407, LRP, MCT6, MOG, MUP10, MUP15, OATP-E, Oatp2, Otoconin 90, otogelin, PBF, PCSK9, periaxin, PFK-2 tes, Phosphogluco-mutase, Pit-1, Placental GH, Prealbumin, Pregnancy Zone protein, RFRP-2, Sg III, SMTNL2, Spot 14, STC1, SULT1A1, Thyroperoxidase, Thyroxine, TR α, TRβ1, TRβ2, TRH-R2, Triiodothyronine, TSHβ, VLDLR, and ZP2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
L-Thyroxine, free acid, 100 mg | sc-207813 | 100 mg | $35.00 | |||
L-Thyroxine, free acid, 500 mg | sc-207813A | 500 mg | $74.00 |